|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/28/12 Ziopharm Oncology Inc 10-Q/A 6/30/12 50:3.1M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q/A Amendment to Quarterly Report HTML 29K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 18K
32: R1 Document and Entity Information HTML 37K
23: R2 Balance Sheets HTML 112K
30: R3 Balance Sheets (Parenthetical) HTML 39K
34: R4 Statements Of Operations HTML 67K
46: R5 Statement Of Stockholders' Equity HTML 66K
24: R6 Statement Of Stockholders' Equity (Parenthetical) HTML 18K
29: R7 Statements of Cash Flows HTML 142K
21: R8 Business HTML 26K
15: R9 Summary of Significant Accounting Policies HTML 19K
47: R10 Collaborations and Alliances HTML 21K
36: R11 Fair Value Measurements HTML 38K
35: R12 Net Loss per Share HTML 23K
40: R13 Related Party Transactions HTML 22K
41: R14 Commitments and Contingencies HTML 53K
39: R15 Warrants HTML 52K
42: R16 Common Stock HTML 19K
31: R17 Stock-Based Compensation HTML 48K
33: R18 Fair Value Measurements (Tables) HTML 27K
38: R19 Net Loss per Share (Tables) HTML 22K
50: R20 Warrants (Tables) HTML 42K
44: R21 Stock-Based Compensation (Tables) HTML 52K
26: R22 Business - Additional Information (Detail) HTML 23K
37: R23 Collaborations and Alliances - Additional HTML 24K
Information (Detail)
28: R24 Assets and Liabilities Measured at Fair Value on HTML 26K
Recurring Basis (Detail)
13: R25 Potential Dilutive Shares Excluded from HTML 26K
Computation of Diluted Net Loss Per Share (Detail)
45: R26 Related Party Transactions - Additional HTML 28K
Information (Detail)
48: R27 Commitments and Contingencies - Additional HTML 121K
Information (Detail)
18: R28 Number of Warrants Outstanding (Detail) HTML 21K
17: R29 Warrants - Additional Information (Detail) HTML 74K
19: R30 Assumptions Used In Binomial Valuation Model and HTML 25K
Black-Scholes Valuation Model (Detail)
20: R31 Warrant Exercise (Detail) HTML 32K
22: R32 Common Stock - Additional Information (Detail) HTML 34K
11: R33 Stock-Based Compensation Expense on All Employee HTML 23K
and Non-Employee Awards (Detail)
43: R34 Stock-Based Compensation - Additional Information HTML 31K
(Detail)
25: R35 Fair Value of Stock Options Assumptions Using HTML 34K
Black-Scholes Option Valuation Model (Detail)
27: R36 Stock Option Activity Under Stock Option Plan HTML 83K
(Detail)
14: R37 Summary of Unvested Restricted Stock (Detail) HTML 46K
49: XML IDEA XML File -- Filing Summary XML 74K
16: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 392K
5: EX-101.INS XBRL Instance -- ziop-20120630 XML 731K
7: EX-101.CAL XBRL Calculations -- ziop-20120630_cal XML 109K
8: EX-101.DEF XBRL Definitions -- ziop-20120630_def XML 650K
9: EX-101.LAB XBRL Labels -- ziop-20120630_lab XML 966K
10: EX-101.PRE XBRL Presentations -- ziop-20120630_pre XML 726K
6: EX-101.SCH XBRL Schema -- ziop-20120630 XSD 147K
12: ZIP XBRL Zipped Folder -- 0001144204-12-048414-xbrl Zip 101K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q/A
(Amendment No. 1)
| (Mark One) | ||
| þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
| For the quarterly period ended June 30, 2012 | ||
| OR | ||
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
Commission File Number 001-33038
ZIOPHARM Oncology, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware (State or other jurisdiction of incorporation or organization) |
84-1475642 (I.R.S. Employer Identification No.) |
1180 Avenue of the Americas, 20th Floor, New York, NY 10036
(646) 214-0700
(Address, including zip code, and telephone number, including
area code, of registrant’s principal executive offices)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period than the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes: þ No: ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes: þ No: ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer ¨ | Accelerated filer þ | Non-accelerated filer ¨ | Smaller reporting company ¨ |
| (Do not check if a smaller reporting company) | |||
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: ¨ No: þ
The number of shares of the registrant’s Common Stock, $.001 par value, outstanding as of July 29, 2012, was 79,567,946 shares.
C:
Explanatory Note
ZIOPHARM Oncology, Inc. is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2012 (“Form 10-Q”), which was filed with the Securities and Exchange Commission on August 2, 2012, for the sole purpose of furnishing XBRL Interactive Data Files. Under Rule 405(a)(2) of Regulation S-T, a filer may submit its first Interactive Data File containing detail-tagged footnotes or schedules within 30-days of the original filing date of the Form 10-Q. No other changes have been made to the Form 10-Q.
Except as specifically described above, this Amendment No. 1 does not reflect events occurring after the filing of the Form 10-Q, does not update disclosures contained in the Form 10-Q and does not modify or amend the Form 10-Q.
Pursuant to Rule 406T of Regulation S-T, the XBRL Interactive Data Files furnished as Exhibits 101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB, and 101.PRE hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended or Section 18 of the Securities Exchange Act of 1934, as amended and otherwise are not subject to liability under such sections.
C:
| C: 2 |
Part II - Other Information
Item 6. Exhibits
Exhibit
Number Exhibit Description
| 31.1* | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2* | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1* | Certifications pursuant to 18 U.S.C. Section 1350 |
101.INS* XBRL Instance Document
101.SCH* XBRL Taxonomy Extension Schema Document
101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF* XBRL Taxonomy Definition Linkbase Document
101.LAB* XBRL Taxonomy Extension Label Linkbase Document
101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document
C:
| 3 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| /s/ Jason A. Amello |
|
Executive Vice President and Chief Financial Officer |
| (Duly Authorized Officer and Principal Financial and Accounting Officer) |
Dated: August 28, 2012
C:
| 4 |
| 31.1* | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2* | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1* | Certifications pursuant to 18 U.S.C. Section 1350 |
101.INS* XBRL Instance Document
101.SCH* XBRL Taxonomy Extension Schema Document
101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF* XBRL Taxonomy Definition Linkbase Document
101.LAB* XBRL Taxonomy Extension Label Linkbase Document
101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document
C:
| 5 |
| This ‘10-Q/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/28/12 | |||
| 8/2/12 | 10-Q, 8-K | |||
| 7/29/12 | ||||
| For Period end: | 6/30/12 | 10-Q | ||
| List all Filings | ||||